

# IDMA BULLETIN

VOL. NO. 53

ISSUE NO. 11 (PAGES: 28)

15 TO 21 MARCH 2022

ISSN 0970-6054

WEEKLY PUBLICATION



## Indian APIs & Formulations for Global Healthcare

INDIAN DRUG MANUFACTURERS' ASSOCIATION

**INDIAN DRUG MANUFACTURERS' ASSOCIATION** SINCE 1961

75 Azadi Ka Amrit Mahotsav

www.idmaconclave.com

**BLOCK YOUR DATES**

14 & 15 APRIL 2022

**INDIAN PHARMA - GLOBAL HEALTH CARE**

60 YEARS

Commemorating IDMA's Diamond Jubilee

2 Days | 25+ Speakers | 5 Panel discussions | 5+ Inspiring talks

Boundless Opportunities To Be Future Ready Atmanirbhar Bharat

#IDMA2022

**LEARN NETWORK SHARE**

An extraordinary platform showcasing accomplishments of the Indian Pharmaceutical Industry. An eclectic atmosphere to exchange ideas and insights with promoter leaders, c-suite professionals and investors. IDMA welcomes you to be a part of the history, relish the present and leapfrog into the future.

Hotel Sahara Star, Mumbai

KNOWLEDGE PARTNER BAIN & COMPANY

**CHIEF GUEST - INAUGURATION CEREMONY**  
**DR. MANSUKH MANDAVIYA**  
Hon'ble Minister of Health and Family Welfare and Chemicals and Fertilizers

**CHIEF GUEST - VALEDICTORY CEREMONY**  
**SHRI PIYUSH GOYAL**  
Hon'ble Minister of Commerce & Industry, Consumer Affairs, Food & Public Distribution and Textiles

**GAIN IDEAS & INSIGHTS ON THE FUTURE OF PHARMA INDUSTRY IN INDIA**

- India's Role in Global Vaccine Development
- Explore Opportunities for Private Equity Investments in Pharma Business
- Understand How to Enhance Value from Manufacturing to Consumer
- Inspiring Management lessons from Ancient Scriptures
- Pharmaceutical Innovations in India
- Roadmap for Positioning India as the Global API Hub

**DO NOT MISS THE OPPORTUNITY TO INTERACT WITH VISIONARIES & CHANGEMAKERS**

For more details write to [actadm@idmaindia.com](mailto:actadm@idmaindia.com)

## HIGHLIGHTS

- ★ **ET Healthworld.com and IDMA : India Pharma World Summit on Technological Disruption in Pharma 2.0 to be held on 25th March 2022 (REGISTER NOW)** (Page No. 7)
- ★ **Aptar Pharma and IDMA Webinar on Stability Challenges on "Enhance Oral Solid Doses Stability and Drug Delivery Devices through the use of Active Packaging" to be held on 1st April 2022 (REGISTER NOW)** (Page No. 8)
- ★ **Need For Participation by Researchers on Related Regulatory Policy Making and Advocacy: Dr. Gopakumar G. Nair** (Page No. 9)

# LIMITLESS DEDICATION. THAT LEADS TO UNQUESTIONABLE **PURITY.**



**Dear Partner,**

It goes without saying that Signet provides excipients only of the highest quality and purity, from global leaders like Pfanstiehl, Galactic and Novo Nordisk Pharmatech A/S.

Pfanstiehl brings over ten decades of experience being at the forefront of the pharmaceutical as well as biotechnology sectors, specialising in high purity and low endotoxin ingredients and intermediates. Galactic are global leaders in the production of lactic acid and mineral lactates, offering purity and quality in equal measure across their products. While Novo Nordisk Pharmatech A/S have been the premier supplier of the finest and safest quaternary ammonium compounds, for over 65 years.

But for us, purity is also a tangible philosophy. One that we practice in make and mind, by always conducting our business with the utmost integrity and transparency.

Signet-ure  
purity



## Pfanstiehl

### LOW ENDOTOXIN GRADES

- Sucrose • Trehalose Dihydrate • D-Galactose
- Maltose Hydrate • D-Mannose • L-Arginine
- L-Arginine Hydrochloride
- L-Histidine Hydrochloride Monohydrate
- L-Histidine • Sodium Succinate Anhydrous
- Sodium Succinate Hexahydrate

Novo Nordisk  
Pharmatech A/S



- FEF BENZALKONIUM CHLORIDE
- FEF BENZALKONIUM CHLORIDE SOLUTION
- FEF CETRIMIDE
- FEF CETYL TRIMETHYL AMMONIUM BROMIDE



- GALACID PHARMA 90 (Lactic acid)
- GALAFLOW SL PHARMA (Sodium Lactate)
- GALAXIUM PEARLS PHARMA  
(Calcium Lactate Pentahydrate)

# Signet

The Complete Excipients Company



**Founder Editor:**  
Dr. A. Patani

**Editor:**  
Dr. Gopakumar G. Nair

**Associate Editors:**  
Mr. J. L. Sipahimalani  
Dr. Nagaraj Rao  
Dr. George Patani

**National President**  
Dr. Viranchi Shah

**Immediate Past National President**  
Mr. Mahesh Doshi

**Senior Vice-President**  
Mr. Bharat N Shah

**Vice-Presidents:**  
Dr. George Patani  
(Western Region)

Mr. Asheesh Roy  
(Eastern Region)

Mr. B K Gupta  
(Northern Region)

Mr. T Ravichandiran  
(Southern Region)

**Hon General Secretary**  
Mr. Mehul Shah

**Hon Joint Secretaries**  
Mr. Kamlesh C Patel  
Mr. Pranav Choksi

**Hon Treasurer**  
Mr. Vinay Pinto

**For information contact :**  
IDMA Secretariat: (H.O.)  
Daara B Patel  
Secretary-General

**Melvin Rodrigues**  
Sr Manager (Commercial & Administration)

IDMA State Boards	Chairman
▶ Gujarat State Board	: Dr. Shrenik K Shah
▶ Haryana State Board	: P K Gupta
▶ Himachal Pradesh & Uttarakhand State Board	: R C Juneja
▶ Karnataka State Board	: S M Mudda
▶ Madhya Pradesh State Board	: Paresh Chawla
▶ Tamil Nadu, Puducherry & Kerala State Board	: J Jayaseelan
▶ Telangana State Board	: Shaik Janimiya
▶ West Bengal State Board	: Shiv Sagar Tewari
IDMA Delhi Office	: Ashok Kumar Madan Executive Director S. Ranganathan Asst. Manager (Administration)

A Publication of  
**Indian Drug Manufacturers' Association**  
102-B, 'A-Wing', Poonam Chambers,  
Dr. A.B. Road, Worli, Mumbai - 400 018  
Tel : 022-2494 4624 / 2497 4308 Fax: 022-2495 0723  
e-mail: publications@idmaindia.com/  
actadm@idmaindia.com/ website: www.idma-assn.org

**Published on 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup> and 30<sup>th</sup> of every month**

**Annual Subscription**  
₹ 1000/- (for IDMA members)  
₹ 2000/- (for Government Research/Educational Institutions)  
₹ 4000/- (for non-members) US\$ 400 (Overseas)  
Please send your payment in favour of  
**Indian Drug Manufacturers' Association**

OPINIONS EXPRESSED BY THE AUTHORS OF INDIVIDUAL ARTICLES  
DO NOT NECESSARILY REPRESENT THE OFFICIAL VIEW OF IDMA.

# IDMA BULLETIN

**Vol. No. 53**

**Issue No. 11**

**15 to 21 March 2022**

## IDMA ACTIVITIES:

IDMA 60th Year Celebrations 2022. ....	4
ET Healthworld.com and IDMA : India Pharma World Summit on Technological Disruption in Pharma 2.0 to be held on 25th March 2022. ....	7
Aptar Pharma and IDMA Webinar on Stability Challenges on "Enhance Oral Solid Doses Stability and Drug Delivery Devices through the use of Active Packaging" to be held on 1 <sup>st</sup> April 2022.....	8
Need For Participation by Researchers on Related Regulatory Policy Making And Advocacy: Dr. Gopakumar G. Nair .....	9
IDMA Congratulates Mr. S V Veeramani, Past National President, IDMA and Chairman, Fourrts (India) Laboratories Pvt. Ltd. for his exemplary Philanthropy work .....	10
Congratulations Dr Viranchi Shah, National President, IDMA on being felicitated at L M College of Pharmacy .....	11
IDMA Congratulates Dr Mansukh L Mandaviya, Minister of Health & Family Welfare and Chemicals and Fertilizers of India on being appointed as the President of AIIMS, New Delhi .....	11
Felicitations and interaction of Dr Viranchi Shah, National President, IDMA at Anand Pharmacy College.....	12

## GOVERNMENT COMMUNICATIONS:

MAI Scheme for Product Registration Charges paid abroad- Eligibility criteria for submission of claims - Reference dates for calculating eligibility criteria for Retention. ....	13
Awards to the leading Pharma and Medical Devices Industry players-India Pharma 2022 & India Medical Devices 2022 .....	14
WHO Proposed List of Nonproprietary Names - reg. ....	15

## INDIAN PHARMACOPOEIA COMMISSION:

Press Release: 20 <sup>th</sup> Skill Development Programme on Pharmacovigilance of Medical Products.....	17
---	----

## DGFT MATTERS:

Operationalisation of new online IT Module for Interest Equalisation Scheme w.e.f. 01.04.2022 .....	18
---	----

## PARLIAMENT NEWS:

In Lok Sabha & In Rajya Sabha .....	19
-------------------------------------	----

## NATIONAL NEWS:

A licence to treat India's health sector .....	26
Advertisements.....	2, 27 & 28



**INDIAN DRUG  
MANUFACTURERS'  
ASSOCIATION**  
SINCE 1961



[www.idmaconclave.com](http://www.idmaconclave.com)

**BLOCK YOUR DATES**

**14** & **15** APRIL 2022

# INDIAN PHARMA - GLOBAL HEALTH CARE



Commemorating IDMA's Diamond Jubilee



**2**  
Days



**25+**  
Speakers



**5**  
Panel  
discussions



**5+**  
Inspiring  
talks



Boundless Opportunities  
**To Be Future Ready**  
Atmanirbhar Bharat

#IDMA2022

## LEARN NETWORK SHARE

An extraordinary platform showcasing accomplishments of the Indian Pharmaceutical Industry. An eclectic atmosphere to exchange ideas and insights with who's who from the industry. An exceptional opportunity to network with promoter leaders, c-suite professionals and investors. IDMA welcomes you to be a part of the history, relish the present and leapfrog into the future.

📍 Hotel Sahara Star, Mumbai

KNOWLEDGE PARTNER  
BAIN & COMPANY



CHIEF GUEST - INAUGURATION CEREMONY

**DR. MANSUKH MANDAVIYA**

Hon'ble Minister of Health and Family Welfare  
and Chemicals and Fertilizers



CHIEF GUEST - VALEDICTORY CEREMONY

**SHRI PIYUSH GOYAL**

Hon'ble Minister of Commerce & Industry,  
Consumer Affairs, Food & Public Distribution and Textiles

### GAIN IDEAS & INSIGHTS ON THE FUTURE OF PHARMA INDUSTRY IN INDIA

India's Role in Global Vaccine Development

Explore Opportunities for Private Equity Investments in Pharma Business

Understand How to Enhance Value from Manufacturing to Consumer

Inspiring Management lessons from Ancient Scriptures

Pharmaceutical Innovations in India

Roadmap for Positioning India as the Global API Hub

**DO NOT MISS THE OPPORTUNITY TO INTERACT WITH VISIONARIES & CHANGEMAKERS**

For more details write to [actadm@idmaindia.com](mailto:actadm@idmaindia.com)



## INDIAN DRUG MANUFACTURERS' ASSOCIATION (IDMA) 1961 – 2021 (60 Glorious Years)

102, Poonam Chambers, A Wing, 1<sup>st</sup> Floor, Dr. Annie Besant Road, Worli, Mumbai - 400 018. Maharashtra, India.

Tel: +91-22-24974308 / 24944624

Email: actadm@idmaindia.com Website: www.idma-assn.org

### **IDMA 60TH YEAR CELEBRATIONS 2022**

Thursday, 14th & Friday, 15th April, 2022

**Hotel Sahara Star, Mumbai**

Dear Member,

Greetings from Indian Drug Manufacturers' Association (IDMA).

We are pleased to inform you that the IDMA 60th Year Celebrations is now scheduled for Thursday, 14th & Friday, 15th April 2022 at Hotel Sahara Star, Mumbai. We thank you for your co-operation and understanding with regards to the delay caused by the third wave of the Covid-19 pandemic and regret any inconvenience caused.

We, at IDMA, humbly request our Members to whole-heartedly participate in the IDMA 60th Year Celebrations by way of Registrations & Advertisements. Your support is very much desirable and necessary in strengthening your Association as well as for the success of any initiatives taken up by your Association. We are sure that with your support the 60th Year Celebrations is going to be a massive and glorious success story in the history of your Association.

We intend to commemorate this historic occasion of the completion of 60 years of our Association with a two days long celebration consisting of Panel Discussions, Technical Sessions and an Entertainment Program to boost the image of our Association as the Premier Association of the Indian Pharmaceutical Industry.

The goal of the Diamond Jubilee Celebrations is to:

- ❖ Showcase Pharmaceutical and Allied Industries across the Globe
- ❖ Disseminating knowledge on various subjects
- ❖ Highlighting the contribution of IDMA to bridge the gap between the Industry and the Ministry

This year at the 60th Year Celebrations, we have invited Eminent National and International personalities to address our members over two days. This event would be graced by Bureaucrats and Ministers from the Central Government as well as the State Government. The key torch bearers of the Pharmaceutical World would be an integral part of this event.

We are pleased to inform you that our Hon'ble **Dr. Mansukh Mandaviya**, Minister of Health & Family Welfare and Chemicals & Fertilizers has confirmed to be the Chief Guest at the Inaugural ceremony on 14th April 2022 and our Hon'ble **Shri Piyush Goyal**, Minister for Commerce & Industry, Consumer Affairs, Food & Public Distribution and Textiles has confirmed to be the Chief Guest at the Valedictory ceremony on 15th April 2022. **Dr. Gnanvatsal Swami Ji** will deliver a Spiritual Address on the 2nd Day. We have Industry Stalwarts who have confirmed their presence for various panel discussion scheduled over the two days, such as **Mr. Dilip Shanghvi** (Sun Pharmaceutical Industries), **Mr. Satish Reddy** (Dr. Reddy's Laboratories), **Dr. Amit Varma** (Quadria Capital), **Mr. Rakesh Jhunjunwala**, **Mr. Dhaval Shah** (PharmEasy), **Mr. K V Subramaniam** (Reliance Life Sciences), **Mr. Premchand Godha** (IPCA Laboratories) and **Mr. Rajeev Nanapaneni** (Natco Pharma).

We are pleased to inform you that **Bain & Co** is our knowledge partner for this event.

As part of the Celebrations, the winners of the:

1. **IDMA Margi Patel Choksi Memorial Best Patent Awards**
2. **IDMA ACG-SCITECH Best Research Paper Awards**
3. **IDMA Corporate Citizen Awards**
4. **IDMA - N. I. Gandhi Chief Mentor Award**

would be announced and the Awards would be presented.

Your Association has come a long way and many milestones have been achieved in the last 60 Years and specially the last two years which have been different, difficult and trying times. You would be pleased to note that during Covid-19 Pandemic, IDMA Secretariat has played an important role in facilitating uninterrupted supply of quality medicines with excellent coordination between the Industry, Government, Regulators and other Associations. Nevertheless, it is due to your untiring efforts and commitment to the wellbeing and prosperity of our Association that we will be completing 60 years of glorious service to our Pharma Industry and to our great Nation.

We are sure you will be an integral part of the Grand Celebrations.

### **IDMA 60th ANNUAL PUBLICATION 2022**

The **IDMA 60th Annual Publication 2022**, an up-to-date and most informative compendium will be released at the Annual Celebrations. This Annual Publication will present statistics, vital data and information on the Pharmaceutical industry. This Publication has also come to be recognized as the indispensable reference book of the Indian Pharmaceutical Industry.

### **AN OFFER NOT TO BE MISSED**

Advertisers can, through this single medium, reach their target audience such as Bulk Drug Manufacturers, Formulators, Researchers, Analysts, Traders, Scientists, Students, Consultants, various Government Officials etc. and leave an enduring impression on everyone connected with the Industry.

<b>ADVERTISEMENT RATES</b>		
<b>SR. NO.</b>	<b>PARTICULARS</b>	<b>RATE PER ADVERTISEMENT (RS.)</b>
1.	Double Spread	1,00,000
2.	Special Bookmark	1,00,000
3.	Full Page (Colour)	50,000
4.	Full Page (Black & White)	30,000

### **OPPORTUNITIES FOR SPONSORSHIPS:**

We would be extremely pleased if you would accept one of the below Sponsorship for this celebrations :-

- PLATINUM SPONSOR : Rs.25 Lakh
- GOLD SPONSOR : Rs.10 Lakh
- DIAMOND SPONSOR : Rs.15 Lakh
- SILVER SPONSOR : Rs.5 Lakh

Sponsors will be provided special benefits & privileges as per the copy attached: For details please contact IDMA Secretariat.

### **REGISTRATION FEES:**

To participate in the 60th Year Celebrations, the registration fee would be as under:

Reception Committee Member	–	Rs.7,500/- plus GST @ 18%
Delegate		Rs.6,000/- plus GST @ 18%

(For more than 4 registrations from one Company, the 5th registration will be complimentary)

For further details, please contact:

<b>Mr. Melvin</b>	<b>Ms. Geeta</b>	<b>Ms. Batul</b>	<b>Ms. Parivaz</b>
9821868758	9820161419	9920045226	9830081744
actadm@idmaindia.com	publications@idmaindia.com	technical@idmaindia.com	idma2@idmaindia.com

### **ROOM RATES :**

We have negotiated Special Room Rates at Hotel Sahara Star for our members. The special room rate would be Rs.6,000/- + GST per night for a Single / Double Occupancy. The room rate includes complimentary breakfast and internet facilities.

Kindly note that those members who desire to stay at Hotel Sahara Star, please forward their details to the IDMA Secretariat.

Your active participation & interaction with the cream of the Pharmaceutical Industry as well as Ministry Officials and Bureaucrats, from the Centre as well as States, will not only add value to your business but also ensure that the flag of our Association continues to fly higher in the Global Pharmaceutical Industry.

Looking forward to your usual fine cooperation in making this historic event a 'सुपर से भी ऊपर' Success.

Thanking you,

With best regards,

**Bharat Shah**  
Chairman, Organizing Committee,  
IDMA 60th Year Celebrations

**Dr. Viranchi Shah**  
National President

**Daara B Patel**  
Secretary - General

SECOND EDITION

#ETIPWS



ET Healthworld.com

# INDIA PHARMA WORLD SUMMIT

Technological Disruption in Pharma 2.0

**MARCH 25, 2022 | VIRTUAL EVENT**

————— We Proudly Present —————



Our **Supporting Partner**

Be a part of the thought leadership that will decode the technological and logistical disruptions in the pharmaceutical sector, ushered in by the entrepreneurial spirits of the veterans and fresh minds of the industry.

**REGISTER NOW**



**Partnership & Marketing Alliance**

ASHISH KUMAR | ashish.kumar3@timesinternet.in | +91 974 076 1921  
SAURAV PRAKASH | c-saurav.prakash@timesinternet.in | +91 828 555 0210

**For Speaking Opportunities & Nomination**

MANVI SAXENA | manvi.saxena@timesinternet.in | +91 886 051 0296  
ANCHAL DWIVEDI | anchal.dwivedi@timesinternet.in | +91 912 027 4773

If you do not want to receive this mailer, you can [Unsubscribe](#) from our mailing list.  
ETHHealthworld(Times Center), FC - 6, Film City, Sector 16A, Noida - 201301, Uttar Pradesh, India



## INDIAN DRUG MANUFACTURERS' ASSOCIATION (IDMA)

102, Poonam Chambers, A Wing, 1st Floor, Dr. Annie Besant Road,  
Worli, Mumbai - 400 018. Maharashtra, India.  
Tel: +91-22-24974308 / 24944624  
E-mail: actadm@idmaindia.com Website: www.idma-assn.org



### **APTAR Pharma and Indian Drug Manufacturers' Association (IDMA) is organizing an Webinar on Stability Challenges**

**on "Enhance Oral Solid Doses Stability and Drug Delivery Devices through the use of Active Packaging"**

**on the Friday, 1<sup>st</sup> April 2022 from 4.00 pm to 5.30 p.m.**

**The Moderator of the Webinar : Mr. S R Vaidya, Chairman, MSME Committee, IDMA**

**The International Speakers for this webinar : Bidet Francois**



**Francois Bidet**

VP Business Development, EMEA  
Aptar CSP Technologies

Francois is the Vice-President of Business Development, EMEA at Aptar CSP Technologies. In this role, he focuses on developing a robust pipeline of opportunities to drive long-term business growth in the EMEA region, across all of the company's application fields.

#### **Abstract**

Stability challenges are likely to increase with the development of more potent APIs, larger molecules, and modified release tablets. Innovative and evolving dosage forms, such as chewable, micro-tablets and orally disintegrating tablets, also face heightened stability and shelf life challenges. These deficiencies are often linked to the presence of moisture and/or oxygen in the packaging headspace.

In this webinar, you will learn how active packaging solutions offer a practical way to increase efficiency and effectiveness of pharmaceutical packaging technology across a range of applications. Explore how 3-Phase Activ-Polymer™ technology can be integrated into blister packaging, stick packs, inhalers, medical devices, bottles, and more to control moisture and/or oxygen in the packaging headspace, ensuring drug product stability and enhancing shelf life.

#### **Key Learning Objectives**

- Understand the impact of packaging choices on stability and shelf life of drugs
- Review best practices and new techniques for the management of microclimate in packaging
- Learn about the benefits of active packaging in challenging environments

Kindly note that there are no registration fees for this webinar but prior registration is compulsory.

Webinar Registration page link : [Webinar \(microsoft.com\)](#)

[https://teams.microsoft.com/registration/PkrXX3rVDkGNfALE3wYiNA,M8Y2FUhaNEmpIW5AtPPojg,H699HZJvpke-twCuPK6LVQ,JDL15H1YS0GicI77MVHx7Q,gNEQGvsX1UyTqGBmE\\_9RiA,SCJODVf6AkaJUM5\\_GYp4Uw?mode=preview](https://teams.microsoft.com/registration/PkrXX3rVDkGNfALE3wYiNA,M8Y2FUhaNEmpIW5AtPPojg,H699HZJvpke-twCuPK6LVQ,JDL15H1YS0GicI77MVHx7Q,gNEQGvsX1UyTqGBmE_9RiA,SCJODVf6AkaJUM5_GYp4Uw?mode=preview)

Looking forward to your support and participation in making this webinar a grand success.

Thanks & regards,

**Daara B Patel**, Secretary – General, **IDMA**



## NEED FOR PARTICIPATION BY RESEARCHERS ON RELATED REGULATORY POLICY MAKING AND ADVOCACY


*Dr. Gopakumar G. Nair, Editor, Indian Drugs*

Dear Reader,

Many bills and proposals are being mooted and moved by the present Government in response to public representations and also to resolve internal constraints and for operational reasons. Regulatory aspects are closely linked to research and innovation. However, the Indian research community appears either not aware of the need or geared up to participate in policy making or amendments to statutes closely linked to researchers, even when some of them act as impediments in progress of research or act as hurdles in their chosen field of investigative or innovative research. Research institutes, public funded laboratories, Universities and even research-based academic conglomerates need to assign or designate an internal or external person or agency to familiarise them, and help generate views, comments and suggestions to make the path of Indian research smooth and friendly to creative contributions. We need to present or represent our concerns or views when the window is open on policy matters.

Review of Intellectual Property Rights Regime in India was undertaken and a Report was submitted by the Parliamentary Standing Committee on Commerce in July, 2021, also for deliberations on the National IPR Policy, 2016. This exhaustive Report (153 pages) is available on [https://rajyasabha.nic.in/rsnew/Committee\\_site/Committee\\_File/ReportFile/13/141/161\\_2021\\_7\\_15.pdf](https://rajyasabha.nic.in/rsnew/Committee_site/Committee_File/ReportFile/13/141/161_2021_7_15.pdf). Thereafter, comments were invited by the DIIPT (Department of Promotion of Industry and Internal Trade) from IP community and the processing of the views and comments are still being done by DIIPT for transmission to the Parliament. A detailed compilation of views (261 pages) has been done by Prof. Dr. Prabuddha Ganguli for submission to DIIPT on patent related amendments. IDMA had actively participated in the post Uruguay Round Dunkel Draft Treaty leading to TRIPs and WTO in 1995. IDMA had actively contributed to the three amendments to

**Dr. Gopakumar G. Nair** is a Ph.D in Organic Chemistry (1966) from National Chemical Laboratory, Pune (Pune University). He was a Post-Doctoral fellow at IIT Bombay, Powai (1967) before joining the Pharma Industry. He was Director of Bombay Drug House P. Ltd., later Chairman of BDH Industries Ltd. as well as CMD of Bombay Drugs & Pharma Ltd., which was merged with Strides Arcolab Ltd. in 2001. Dr. Nair served IDMA as office bearer for many years from 1972 onwards and was Chairman of various Committees for nearly 4 decades. He was the President of IDMA in 1999/2000. Currently, Dr. Nair is the Chairman of the IPR Committee in IDMA.



Having moved into the Intellectual Property field, he was the Dean of IIPS (Institute of Intellectual Property Studies) at Hyderabad in 2001/2002. Later, he set up his own boutique IP firm, Gopakumar Nair Associates, as well as Gnanlex Hermeneutics Pvt. Ltd., having done his L. L. B. from Mumbai University. He is also CEO of Patent Gurukul and President of Bharat Education Society, Kurla, Mumbai, managing many educational institutions in and around Mumbai.

Patents Act, 1970 to make the Indian Patent law provisions a well-balanced one, with rights and obligations, taking advantage of the flexibilities available in TRIPs. If IDMA members and Indian Research Organizations require amendments in the Patent Act, 1970, or in other IP forms and portfolio, this is the right opportunity.

Biodiversity Act, 2002 and Biodiversity Rules, 2004 have been subject of many representations and grievances. Another Bill introduced in Lok Sabha and which

is extremely important for Indian Pharma, Biotechnology and Natural Product Research is the Biological Diversity (Amendment) Bill, 2021. The proposed Bill has addressed many concerns brought to the attention of the NBA (National Biodiversity Authority) and the Government especially in Sections 3, 4, 5 and 6 which are relevant for research community. A full-page advertisement in Economic Times on Biotechnology Policy 2022- 27 announcing new Biotechnology Policy for Gujarat could not have missed out. It is in this context, that the need for

more participation by research community in regulatory policy is required and recommended. The Government of India and the Ministries appear to be keen to receive suggestions and open to respond with needful corrective and improvement steps.

Let us make 2022 a productive breakthrough year for Indian Pharma-Biotech research, equipped with all the right inputs.

Courtesy: Indian Drugs, Editorial, 59 (01), January 2022



## **IDMA Congratulates Mr. S V Veerramani, Past National President, IDMA and Chairman, Fourrts (India) Laboratories Pvt. Ltd. for his exemplary Philanthropy work**



Mr. S V Veerramani, Past National President, IDMA and Chairman, Fourrts (India) Laboratories Pvt. Ltd., has sponsored a Mobile Clinic cum Vaccination Van for Rotary Club of Adyar (Dist 3232). Rtn J Sridhar, District Governor-RI District 3232 inaugurated the Mobile Clinic cum Vaccination Van on 17th March 2022 at The Hindu Mission Hospital, Tambaram. Mr. S V Veerramani, handover the keys to Mr D K Srinivasan, Padma Awardee, Founder Honorary Secretary, Hindu Mission Hospital, Tambaram.



## **Congratulations Dr Viranchi Shah, National President, IDMA on being felicitated at L M College of Pharmacy**



Dr Viranchi Shah was felicitated on being appointed as National President IDMA at the L M College of Pharmacy, Ahmedabad on 17<sup>th</sup> February 2022. Dr H G Koshia, Shri Jayant Kumar, Shri Vinitbhai, Dr Chabaria, Dr Shrenik Shah, Shri Sumit Agrawal, Shri V R Shah, Dr J B Dave, Shri Kamlesh Patel, Shri Nirav Mehta, Industry stalwarts, LMCP faculties and students were present at the function.



## **IDMA Congratulates Dr Mansukh L Mandaviya, Minister of Health & Family Welfare and Chemicals and Fertilizers of India on being appointed as the President of AIIMS, New Delhi**



## Felicitation and interaction of Dr Viranchi Shah, National President, IDMA at Anand Pharmacy College



Dr Viranchi Shah, National President, IDMA was felicitated at the Annual function of Anand Pharmacy College, Anand, Gujarat held on 11<sup>th</sup> March 2022. President interacted with Pharmacy students in presence of Chemistry Guru – Dr B N Suhagia and Dr Tejal Gandhi and other dignitaries.



**For Advertising in the Classified Columns and also for series advertisements please contact: Geeta Suvarna (+9820161419) Publications Department**



### **IDMA BULLETIN**

Tel.: 022 - 2494 4624 / 2497 4308 / Fax: 022 - 2495 0723/

E-mail: [publications@idmaindia.com](mailto:publications@idmaindia.com),

Website: [www.idma-assn.org](http://www.idma-assn.org), [www.indiandrugsonline.org](http://www.indiandrugsonline.org)

## **MAI Scheme for Product Registration Charges paid abroad- Eligibility criteria for submission of claims - Reference dates for calculating eligibility criteria for Retention**

PXL/HO/Cir-148/2021-22, dated 11<sup>th</sup> March 2022

***Association have received a communication from Mr Uday Bhaskar, Director- General, Pharmaceuticals Export Promotion Council of India (Pharmexcil), (Set up by Ministry of Commerce & Industry, Government of India), Hyderabad, dated 11th March 2022 on the above subject as reproduced below:***

In continuation to the Pharmexcil circular PXL/HO/Cir-004/2021-22 dated: 22.04.2021 it is to bring to your kind notice that the reference dates for calculating eligibility criteria for submitting the MAI claims for Retention of products for certain countries are modified considering the constraints faced by the applicants.

The Product registration certificates, Re-registration and Renewal certificates issued by the Overseas Drug Regulatory authorities are clearly reflecting the date of issue of certificate. However in the case of annual retentions required by some countries (eg: Kenya, Tanzania, Switzerland, Uganda and Zambia), it is observed that applicants are required to make the payment for annual retention fee but the Regulatory agencies are not issuing the Retention certificate. It has become a challenge for applicants to provide the evidence of granting the retention certificate and the reference date required to initiate MAI claims.

**Hence, in those cases, wherever Regulatory agency is not issuing a product retention certificate the PAYMENT RECEIPTS issued by the overseas regulatory authority for retention of the products will be considered as a reference document for calculating the stipulated timeline for submitting the MAI claim applications.**

**In cases where the product retention certificates and receipts are not issued by the regulatory agency, INVOICES will be considered as the reference document for calculating the eligibility criteria for submitting the claims.**

We are giving below some examples for Retention of Product approvals:

Malawi : Retention certificates  
Uganda, Tanzania, Zambia & Kenya : Payment Receipt for Retention  
Switzerland : Invoices for Retention

Member companies are advised to submit the claims considering the above reference documents for calculating the defined timelines (i.e 45 days). For any further clarifications, members may write to Dr. Gayatri, Assistant Director (email id: research@pharmexcil.com).



# Awards to the leading Pharma and Medical Devices Industry players-India Pharma 2022 & India Medical Devices 2022

F. No.35024/02/2022-Scheme, dated 11<sup>th</sup> March, 2022

Dear Members,

We have received a communication from DoP for the above mentioned subject. Department of Pharmaceuticals organizes "Annual India Pharma & India Medical Devices" event every year with collaboration with Federation of Indian Chambers of Commerce & Industry (FICCI).

Department confers awards to the leading Industrial Players in the field of Pharmaceuticals and Medical Devices sector, based on their performance on the select indicators and the Awards are presented by the Hon'ble Union Minister of Chemicals and Fertilizers.

The Department of Pharmaceuticals is organizing the 7th edition of the event i.e. "India Pharma 2022 & India Medical Devices 2022" in the last week of April 2022. The Department is proposing certain awards in the field of Pharmaceuticals and Medical Devices sector. The categories of Awards for 2022 are given in the Annexure (attached).

Eligible members are requested to apply for the preferred award category. The forms will be accepted through online mode and the online portal will be available for applying from 14th March 2022 onwards till the end of April 2022.

The members may apply through online only. The link is : <http://dashboard.pharmaceuticals.gov.in/awards/>

Members are requested to peruse and take the benefit of same.

Thanks and regards,

Daara Patel

**Secretary - General**

Department of Pharmaceuticals organizes "**Annual India Pharma & India Medical Devices**" event every year with collaboration with Federation of Indian Chambers of Commerce & Industry (FICCI). During this annual event, the Department confers awards to the leading Industrial Players in the field of Pharmaceuticals and Medical Devices sector, based on their performance on the select indicators and the Awards are presented by the Hon'ble Union Minister of Chemicals and Fertilizers.

The Department of Pharmaceuticals will be organizing 7th edition of the event i.e. "**India Pharma 2022 & India Medical Devices 2022**" in the last week of April 2022. The Department is proposing certain awards in the field of Pharmaceuticals and Medical

Devices sector. The categories of Awards for 2022 are given in the Annexure. Guidelines of the award are also attached for reference.

Eligible Players are requested to apply for the preferred award category. The forms will be accepted through online mode and the online portal will be available for applying from 14th March 2022 onwards till the end of April 2022.

Encl: As above.

**F. No.35024/02/2022-Scheme**

*N. K. Joshi, Under Secretary, Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, New Delhi.*

**Annexure on the category of Awards for the ensuing  
“India Pharma 2022 & India Medical Devices 2022”**

Sr. No.	Category	Name of Award
1.	Leaders Category Awards	India Pharma Leader Award
		India Medical Devices Leader Award
2.	Company of the year Awards	India Pharma Bulk Drug company of the year Award
		India Formulation Company of the year Award
		India Medical Device company of the year Award
3.	MSME Category Awards	India Pharma/API MSME of the year Award
		India Medical Device MSME of the year Award
4.	Start-up Category Awards	India Pharma Start-up of the year Award
		India Medical Device Start-up of the year Award
5.	Innovation Category Award	India Pharma Innovation of the year Award
		India Medical Device Innovation of the year Award
6.	CSR Category Award	India Pharma CSR company of the year Award



## WHO Proposed List of Nonproprietary Names - reg.

**F.No. 31020/1/2020-Policy, dated 16<sup>th</sup> March, 2022**

To  
IPA/IDMA/OPPI/Pharmexcil/Laghu Udyog Bharati/SPIC/CIPI/  
FICCI and Pharma Bureau.

- I am directed to enclose a copy of World Health Organization Circular Letter No. C.L.4.2022 dated 04.02.2022 along with a list of proposed International Nonproprietary Names (prop. INN) of Pharma Substances published by WHO in who Drug Information, Vol.35, No. 4, 2021.

- It is requested to provide comments, if any, on notification of a conflict between proposed names and existing proprietary names at the earliest.
- This issues with the approval of competent Authority.

*Sanjay Meena, Section Officer, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, Shastri Bhawan, New Delhi.*

## WHO Circular Letter No. C.L.4.2022

The World Health Organization presents its compliments and has the honour to transmit, in accordance with Article 3 of the "Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances"<sup>1</sup>, a list of proposed international nonproprietary names (prop. INN) which has been published by the World Health Organization in *WHO Drug Information*, Vol. 35, No. 4, 2021.

It would be appreciated if this communication could be forwarded to the appropriate patent and trade-mark office and to any other organization dealing with the introduction of nonproprietary names for pharmaceutical substances. Any comments that may be made, or notifications of a conflict between proposed names and existing proprietary rights, should be addressed to the INN Programme, World Health Organization, 1211 Geneva 27, within four months following the publication of the above-mentioned journal,

- p.INN list 126 from p. 929 to 1127 (deadline for objecting and commenting is **27 May 2022**)
- p.INN list 126 – COVID-19 (special edition) p. 1129 to 1146 (deadline for objecting and commenting is **27 May 2022**).

The World Health Organization furthermore has the honour to transmit, in accordance with the "International Nonproprietary Names for Variant COVID-19 Vaccine Active Substances" document available on WHO website: [https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-\(inn\)/21-520\\_inn\\_for\\_vocs.pdf?sfvrsn=9b14f30\\_6&download=true](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/21-520_inn_for_vocs.pdf?sfvrsn=9b14f30_6&download=true) (INN Working Document 21.520 April 2021), the following list of proposed international nonproprietary names (prop. INN) which

has been published by the World Health Organization on the WHO website at <https://www.who.int/publications/i/item/who-drug-information---volume-35-no.-4>. It would be appreciated if this communication could be forwarded to the appropriate patent and trade-mark office and to any other organization dealing with the introduction of nonproprietary names for pharmaceutical substances. Any comments that may be made, or notifications of a conflict between proposed names and existing proprietary rights, should be addressed to the INN Programme, World Health Organization, 1211 Geneva 27, within two weeks following the publication on the WHO website for:

- p.INN list 126 – COVID-19 (special edition) **ADDENDUM** p.1147-1148 (deadline for objecting and commenting is **11 February 2022**)

The selection of international nonproprietary names by the World Health Organization for use in all Member States presents many difficulties. It would therefore be appreciated if this were borne in mind when it is contemplated to exercise the right to raise objections.

Furthermore, the World Health Organization would be grateful if, in the interest of public health and pursuant to the procedure referred to in the first paragraph of this communication, the ... enclosed list of names\* could be granted protection in Member States during the period they are under consideration by the World Health Organization as international nonproprietary names.

**Note** : p.INN list 126 from p. 929 to 1127 not been reproduced. Interested members can visit <https://www.who.int/publications/m/item/inn-pl-126> for details.

---

<sup>1</sup>Annex to resolution EB15.R7, Off. Rec. Wld Hlth Org., No. 60, pp. 3 and 55. This text was amended by resolution EB43.R9, Off. Rec. Wld Hlth Org., No. 173, p. 10 and resolution EB115.R4, Executive Board, 115th Session, Resolutions and Decisions (EB115/2005/REC/1), p. 2.

ENCL.: (1) ) \* Prop. INN: List 126, List 126 – COVID-19 (Special edition), List 126 – COVID-19 (Special edition) ADDENDUM published in WHO Drug Information Vol. 35, No. 4, 2021.





## Press Release: 20<sup>th</sup> Skill Development Programme on Pharmacovigilance of Medical Products


The National Coordination Centre for Pharmacovigilance Programme of India (NCC-PvPI) located at Indian Pharmacopoeia Commission Ghaziabad, organized the 20<sup>th</sup> Skill Development Programme on Pharmacovigilance for Medical Products from 07<sup>th</sup> to 11<sup>th</sup> March, 2022 through virtual mode. The training started with welcome address by Dr. Jai Prakash, Officer-in-Charge, PvPI and extended his warm greetings and best wishes to all the participants on behalf of IPC.

A total of 81 registered participants from Puducherry, Uttar Pradesh, Tamil Nadu, Kerala, Maharashtra, Karnataka, Telangana, Delhi, Andhra Pradesh, Odisha, West Bengal, Uttarakhand, Punjab, Bihar, Madhya Pradesh, Rajasthan, Jammu and Kashmir participated in this training programme. The participants included Academicians, Pharmacy Students, Medical Students,

Industry Professionals, Physicians, Pharmacist, Pharmacovigilance Associate across the country. Dr. Shashi Bhushan, Dr. R.S Ray, Mr. Hammad Ali, Mr. Akash Deep Rawat, Mr. Girjesh Vishwakarma, Mr. Tarun Kumar from NCC PvPI supported during the workshop.

During the 5 days Skill Development Programme, 19 technical sessions were conducted on various topics of Pharmacovigilance including Basics of Pharmacovigilance to in-depth Signal detection method and Regulatory intervention/outcomes in an understandable language to the participants. Prof. Y K Gupta, National Scientific Coordinator PvPI addressed all participants by his closing remarks. All participants appreciated the Skill Development Programme.

Note: Please visit IPC website ([www.ipc.gov.in](http://www.ipc.gov.in)) for regular updates.



Have you renewed your  
Membership for the years

**2021-2022 & 2022-2023**

If not, please do so; kindly contact IDMA Secretariat at:  
Email: [actadm@idmaindia.com](mailto:actadm@idmaindia.com) / [accounts@idmaindia.com](mailto:accounts@idmaindia.com)  
Tel.: 022 - 2494 4624 / 2497 4308 / Fax: 022 - 2495 0723

# Operationalisation of new online IT Module for Interest Equalisation Scheme w.e.f. 01.04.2022

DGFT Trade Notice No.38/2021-22, dated 15<sup>th</sup> March 2022

To,

1. All IEC Holders/Members of Trade & Industry
2. All Concerned banks and its branches
3. All RAs of DGFT
4. Export Promotion Councils/Commodity Boards/ other Industry Associations.

1. Attention of the trade and industry is drawn towards the extension of the Interest Equalisation Scheme (IES) upto 31.3.2024, as notified by RBI vide its circular no. DOR.STR.REC.93/04.02.001/2021-22 dated 08.03.2022. In order to capture granular data about the beneficiaries of the scheme and its effective monitoring, it has been decided to operationalise a new online module for filing of electronic registration for Interest Equalisation Scheme w.e.f. 01.04.2022.

2. All exporters seeking benefit under the Interest Equalisation Scheme need to apply online by navigating to the DGFT website (<https://dgft.gov.in>) → Services → Interest Equalisation Scheme. **A Unique IES Identification Number (UIN) will get generated automatically which is required to be submitted to the concerned bank when availing Interest Equalisation** against their pre and post shipment rupee export credit applications.

3. For generating UIN the following steps need to be followed by all concerned exporters -

- i. As a first step, any exporter seeking to apply under IES, need to register on the DGFT Website (if not already registered). It may be ensured that applicant's IEC is linked to its online account, the IEC (ANF-2A) and the Exporter-Importer Profile(ANF-1) is updated to reflect correct and up-to-date details.
- ii. Thereafter, exporter need to login with its registered credentials → navigate to Services → Interest Equalisation Scheme → Apply for Interest Equalisation Scheme and fill in the required details. Basic data about the applicant's IEC would get auto-populated.
- iii. An acknowledgement containing Unique IES Identification Number (UIN) would be auto-generated when duly completed application is submitted online.

- iv. An SMS and email intimation of the UIN generated will be sent to the registered email account and mobile number of the exporter.
  - v. The user charge for generating a UIN shall be 200 and is to be paid online.
  - vi. After generation of the UIN no changes will be allowed. In case of any correction/amendment exporter may generate new UIN.
4. The UIN generated shall have a validity of 1 year from the date of registration, during which an application for availing benefit of IES can be submitted to the concerned bank. **The auto generated Acknowledgement containing UIN number need to be submitted to the concerned bank alongwith the prescribed application by the bank, if any, for availing benefit under IES.**
  5. It will be mandatory for exporter to submit UIN acknowledgment to concerned bank for all applications made on or after 01.04.2022.
  6. Banks will continue to scrutinize and issue benefits as per their own internal process. The guidelines for the bank for validation of submission made by the exporter are being issued separately through RBI.
  7. For any help and guidance on this new process, the Help Manual & FAQs may be accessed on DGFT Website (<https://dgft.gov.in>) → Learn → Application Help & FAQs. For any further assistance, any of the following channels may be accessed-
    - i. Raise a service request ticket through DGFT Helpdesk service under Services → 'DGFT Helpdesk Service'.
    - ii. Call the DGFT Toll-free-Helpline number.
    - iii. Send an email to the Helpdesk on [dgftedi@gov.in](mailto:dgftedi@gov.in)
  8. This issues with the approval of the Competent Authority.

**File: 01/94/180/347/AM20/PC-4**

*Dr D C Dabhale, Deputy Director General of Foreign Trade, Directorate General of Foreign Trade, Ministry of Commerce and Industry, Department of Commerce, New Delhi.*



## In Lok Sabha & In Rajya Sabha

### In Rajya Sabha

#### **Financial Assistance under ECLGS**

#### **Rajya Sabha Unstarred Question No. 1394**

**Shri Brijlal:**

**Q.** Will the Minister of **MICRO, SMALL AND MEDIUM ENTERPRISES** be pleased to state:

- the number of Micro, Small and Medium Enterprises (MSMEs) that have been provided financial assistance under the Emergency Credit Line Guarantee Scheme (ECLGS) of Government during the Coronavirus crisis;
- the number of households got rid of the livelihood crisis; and
- the details thereof?

#### **Answered on 14<sup>th</sup> March 2022**

- A.** (a) to (c): Emergency Credit Line Guarantee Scheme (ECLGS) is administered by Department of Financial Services (DFS), Ministry of Finance. As reported by DFS, as on February 28, 2022 total 104 lakh micro, 5.27 lakh small and 2.65 lakh medium enterprises have been provided financial assistance under ECLGS.

**Minister of State for Micro, Small and Medium Enterprises (Shri Bhanu Pratap Singh Verma)**

#### **MSMES Engaged in Manufacturing and Services**

#### **Rajya Sabha Unstarred Question No. 1399**

**Shri Jawhar Sircar:**

**Q.** Will the Minister of **MICRO, SMALL AND MEDIUM ENTERPRISES** be pleased to state:

- the latest estimate of the numbers of each category of Micro, Small and Medium Enterprises engaged in manufacturing and services;
- their State-wise distribution of all 6 categories and

the estimated employment and economic value; and

- how many of them were affected or shut down by demonetisation and the introduction of Goods and Service Tax (GST) and whether there is any improvement at present?

#### **Answered on 14<sup>th</sup> March 2022**

- A.** (a) & (b): As per 73rd Round of NSS Report on Unincorporated Non-Agricultural Enterprises' (July 2015- June 2016) conducted by Ministry of Statistics & PI (MoSPI), the estimated number of enterprises engaged in manufacturing and services are given below:

Activity	Micro	Small	Medium
Manufacturing	1,95,99,224	65,570	76
Services	2,05,17,480	1,62,625	4,592

State/UT wise distribution of estimated number of enterprises as per 73rd Round of NSS Report on Unincorporated Non-Agricultural Enterprises engaged in manufacturing and services category wise is attached as annexure I.

As per 73rd Round of NSS Report on Unincorporated Non-Agricultural Enterprises (July 2015- June 2016) conducted by Ministry of Statistics & PI (MoSPI), the estimated number of persons employed in MSMEs are about 11.10 crore.

As per the information received from Ministry of Statistics & Programme Implementation, the share of MSME Gross Value Added (GVA) in All India GDP at current prices for the year 2019-20 was around 30%.

(c): As MSMEs are present in both formal and informal sector, data regarding shutdown due to demonetization and GST in MSME sector are not maintained by the Government of India in Ministry of Micro, Small and Medium Enterprises (MSME).

**Minister of State for Micro, Small and Medium Enterprises (Shri Bhanu Pratap Singh Verma)**

**Annexure referred to in reply to part (a)&(b) of Rajya Sabha unstarred Question No. 1399 for answer on 14.03.2022.**

Sr. No.	State/UT	Estimated number of enterprises as per NSS 73rd Round					
		Manufacturing			Services		
		Micro	Small	Medium	Micro	Small	Medium
1	Andhra Pradesh	1019743	1210	0	1440791	10207	290
2	Arunachal Pradesh	972	0	0	3960	208	0
3	Assam	202908	280	0	339595	1869	0
4	Bihar	768324	103	0	1168151	1808	2
5	Chhattisgarh	194353	439	0	243090	1787	228
6	Delhi	178361	2752	0	322010	2942	0
7	Goa	11734	27	0	21502	375	0
8	Gujarat	1205384	35507	0	1023134	5746	114
9	Haryana	181326	1565	31	328783	8778	58
10	Himachal Pradesh	93576	329	0	172622	4899	22
11	Jammu & Kashmir	234241	153	0	176476	2375	5
12	Jharkhand	494056	76	0	480468	6463	51
13	Karnataka	1247016	1728	0	1192197	5882	42
14	Kerala	544268	1551	0	1078260	12383	334
15	Madhya Pradesh	831813	1342	0	758824	11090	925
16	Maharashtra	1239829	3431	0	1627619	9561	392
17	Manipur	63982	77	0	46113	267	0
18	Meghalaya	15833	4	0	34164	126	0
19	Mizoram	8283	0	0	8528	68	0
20	Nagaland	16052	1	0	21899	251	85
21	Odisha	485938	413	0	700796	2299	278
22	Punjab	383018	670	0	502902	3971	58
23	Rajasthan	749764	1161	45	863393	12860	316
24	Sikkim	2408	4	0	11521	169	0
25	Tamil Nadu	1739595	5025	0	1663798	13631	86
26	Telangana	1142825	361	0	805459	5136	430
27	Tripura	50017	67	0	64618	199	0
28	Uttar Pradesh	2205404	4114	0	2762882	22259	332
29	Uttarakhand	71942	201	0	153650	1897	19
30	West Bengal	4175466	2926	0	2417097	12234	523
31	A & N Islands	2592	8	0	8928	53	2
32	Chandigarh	6712	21	0	25872	236	0
33	Dadra & Nagar Haveli	4612	17	0	4175	518	0
34	Daman & Diu	1628	7	0	2446	1	0
35	Lakshadweep	738	0	0	499	0	0
36	Puducherry	24511	0	0	41258	77	0
	<b>ALL</b>	<b>19599224</b>	<b>65570</b>	<b>76</b>	<b>20517480</b>	<b>162625</b>	<b>4592</b>

---

## Udyam Portal

---

### Rajya Sabha Unstarred Question No. 1403

**Shri Subhas Chandra Bose Pilli:**

**Q.** Will the Minister of **MICRO, SMALL AND MEDIUM ENTERPRISES** be pleased to state:

- (a) details of the total number of Micro, Small and Medium Enterprises (MSMEs) registered on the UDYAM portal as of October 2021;
- (b) whether Government is aware that for most MSMEs, compliance costs exceed the post-registration;
- (c) benefits of registering on the UDYAM portal and the details thereof;
- (d) whether Government has provided any incentives to increase registration of MSMEs on the portal;
- (e) if so, the details thereof and, if not, the reasons therefor;
- (f) whether Government has taken any measures to create awareness about the portal; and
- (g) if so, the details thereof and, if not, the reasons therefor?

### Answered on 14<sup>th</sup> March 2022

**A.** (a): The total number of MSMEs which had registered on the Udyam Registration (UR) portal as on 31.10.2021 and had been classified as micro, small and medium enterprises was 54,97,869. Out of this, 51,79,964 were micro; 2,85,540 were small and 32,365 were medium.

(b): Udyam Registration is free of cost, transparent, online, hassle free and is based on self-declaration. It does not require any documents to be uploaded and has an automatic integration with the databases of IT and GSTN and has no compliance cost associated with it.

(c) to (e): Benefits of Registration on UR portal are as under:

- (i) UR is a permanent registration and a basic identification number for an enterprise.
- (ii) UR is paperless and based on self-declaration.
- (iii) There is no need for renewal of UR.
- (iv) Any number of activities including manufacturing or service or both may be specified or added in one Registration.

(v) Along with the Udyam Registration, enterprises may register themselves on GeM (Government e-Market place, a portal for G to B) & SAMADHAAN Portal (a portal to address issues relating to delay in payments) and simultaneously MSMEs themselves can also onboard on TReDS Platform.

(vi) The Udyam Registration may also help MSMEs in availing the benefits of Schemes of Ministry of MSMEs.

(vii) UR Registered MSMEs become eligible for priority sector lending from Banks.

(f) & (g): The Government has created awareness about the UR portal through advertisement in print and electronic media, special campaigns and interaction with stakeholders and Industry Associations.

**Minister of State for Micro, Small and Medium Enterprises (Shri Bhanu Pratap Singh Verma)**

## In Lok Sabha

---

### Disposal of Medical Waste

---

### Lok Sabha Unstarred Question No. 1859

**Shri Sanjay Seth:**

**Shri Jayadev Galla:**

**Q.** Will the Minister of **ENVIRONMENT, FOREST AND CLIMATE CHANGE** be pleased to state:

- (a) whether there is a large amount of medical waste in the country and if so, whether its quantity has increased even more during the corona transition period;
- (b) whether any information or data is available with the Government to ascertain the quantity of medical waste collected per annum in the country;
- (c) whether the Government has released biomedical waste guidelines for COVID wastes and if so, the details of the number of violations that has occurred under these guidelines along with State-wise classification of the same;
- (d) the number of Common Bio-medical Waste Treatment and Disposal Facility (CBWTF) in the country along with the State-wise classification of the same;
- (e) the channels incorporated by States without CBWTF in disposing Bio-medical waste along with the plan for the disposal of the Medical-waste;

- (f) the safeguards afforded to the manual scavengers and waste collectors during the COVID crisis; and
- (g) whether the allocation for research on different methods of waste treatment, to assess and improve their sustainability and efficacy has been made by the Government and if so, the details thereof if not, the reasons therefor?

**Answered on 14<sup>th</sup> March 2022**

**A.** (a)&(b) The Central Pollution Control Board (CPCB) compiles country-wide annual data of bio-medical waste (BMW) generation, collection and treatment based on the annual reports submitted by respective State Pollution Control Boards/ Pollution Control Committees (SPCBs/ PCCs). About 656 Tons/Day (TPD) of BMW was generated in the year 2020, out of which 590 TPD was collected and treated by the Common Biomedical Waste Treatment facilities (CBWTFs). Further, about 84.61 TPD of incremental COVID-19 BMW was generated between May 2020 to February 2022 in the country from healthcare facilities, quarantine centres/ camps, sample collection centres, laboratories, home care/ home isolations centres engaged in treatment, diagnosis and quarantine of COVID-19 infected or suspected patients.

(c) The CPCB had issued “Guidelines for Handling, treatment and disposal of waste generated during treatment, diagnostics and quarantine of COVID-19 patients” in March, 2020 and developed an application namely, COVID19 BWM to track the generation and treatment of COVID-19 BMW at CBWTFs. There are no reported cases of violation of Guidelines; however, the CPCB has issued notices to 33 nos. of CBWTFs across the country for not reporting data on COVID19BWM, as mentioned below:

- Fifteen (15) in Karnataka
- Five (5) in Maharashtra
- Two (2) CBWTFs each in Bihar, Gujarat, Jharkhand, Madhya Pradesh and Telangana
- One (1) each in Odisha, Rajasthan and Uttar Pradesh.

(d) There are 208 Common Bio-medical Waste Treatment Facilities (CBWTFs) operational in the country for treatment and disposal of Bio-medical

Waste (BMW) as per the information furnished by SPCBs/ PCCs for the year 2020. The State/ UTwise details are Annexed.

(e) There are no operational CBWTFs in nine (9) States/ Union Territories. The BMW treatment and disposal in these areas is done through captive treatment facilities operated by healthcare facilities themselves.

(f) To ensure safety of workers engaged in BMW handling and collection, the CPCB guidelines on “Handling, treatment and disposal of waste generated during treatment, diagnostics and quarantine of COVID-19 patients” prescribe for regular sanitization and provision of adequate personal protective equipment like three layer masks, splash proof aprons/gowns, nitrile gloves, gum boots and safety goggles.

(g) The Biomedical Waste Management Rules, 2016 (BMWM Rules, 2016) notified by the Ministry of Environment, Forest and Climate Change, (MoEFCC) stipulates source segregation of BMW into four categories and prescribe category-specific effective technological options like incineration, autoclaving, microwaving, hydroclaving and chemical disinfection. The BMWM Rules, 2016 also include provisions to adopt new technologies for BMW treatment, after validation. Further, the MoEFCC is also implementing a central sector scheme to provide financial support to innovative research projects aimed at environmentally sound management of waste, including BMW.

**Annexure**

**ANNEXURE REFERRED TO IN PART (d) OF LOK SABHA UNSTARRED QUESTION NO. 1859 DUE FOR REPLY ON 14/03/2022 REGARDING ‘DISPOSAL OF MEDICAL WASTE’ RAISED BY HON’BLE MEMBER OF PARLIAMENT SHRI SANJAY SETH AND SHRI JAYADEV GALLA**

**State-wise details of Operational CBWTFs in India**

<b>Name of the State/Union Territory</b>	<b>Operational CBWTFs</b>
Andaman Nicobar	Nil
Andhra Pradesh	12
Arunachal Pradesh	Nil

Assam	1
Bihar	4
Chandigarh	1
Chhattisgarh	4
Daman & Diu and Dadra & Nagar Haveli	Nil
Delhi	2
Goa	Nil
Gujarat	20
Haryana	11
Himachal Pradesh	3
Jharkhand	4
Jammu & Kashmir	3
Karnataka	25
Kerala	1
Ladakh	Nil
Lakshadweep	Nil
Madhya Pradesh	12
Maharashtra	30
Manipur	1
Meghalaya	1
Mizoram	Nil
Nagaland	Nil
Odisha	6
Puducherry	1
Punjab	5
Rajasthan	11
Sikkim	Nil
Tamil Nadu	10
Telangana	11
Tripura	Nil
Uttarakhand	2
Uttar Pradesh	21
West Bengal	6
Director General Armed Forces Medical Services (DGAFMS)	Nil
<b>Total</b>	<b>208</b>

(Source:CPCB)

**Minister of State in the Ministry of Environment, Forest and Climate Change  
(Shri Ashwini Kumar Choubey)**

## **Use of Cryptocurrency for Money Laundering**

### **Lok Sabha Unstarred Question No. 1918**

**Shri Rakesh Singh:**

**Q.** Will the Minister of **FINANCE** be pleased to state:

- whether the Government is aware of the use of cryptocurrency for money laundering by cyber criminals and if so, the details thereof;
- whether there is an apprehension of money laundering activities in the country through this and if so, the details thereof; and
- whether the Government has identified people involved in such activities in the country and if so, the details thereof?

**Answered on 14<sup>th</sup> March 2022**

**A.** (a) & (b): Yes Sir. Reports have been received from Law Enforcement Agencies (LEAs) in connection with usage of cryptocurrency by cyber criminals. Directorate of Enforcement (ED) is investigating 07 cases under PMLA, 2002 in which cryptocurrency has been used for Money Laundering. Cases investigated by ED under PMLA, reveals that accused have laundered Proceeds of Crime (PoC) through cryptocurrency.

(c): Yes Sir, investigations conducted by Enforcement Directorate so far, revealed that some foreign nationals and their Indian associates have laundered the PoC through cryptocurrency accounts at certain exchange platforms. In one of such case an accused has been arrested by ED in the year 2020 for facilitating the foreign related accused companies to launder the PoC by converting money generated out of crime into cryptocurrency and thereafter transfer to foreign countries. Prosecution Complaint has been filed in this case before the Special Court, PMLA. So far, ED has attached PoC amounting to Rs. 135 Crore (approx.) under PMLA in above mentioned cases.

**Minister of State in the Ministry of Finance  
(Shri Pankaj Chaudhary)**

---

## Taxes on Multinational Companies

---

### Lok Sabha Unstarred Question No. 1924

**Shri Ritesh Pandey:**

**Q.** Will the Minister of **Finance** be pleased to state:

- (a) whether the Government has presently any plans, policies and rules to levy proper share of taxation on multinational companies which derive large revenues from India via their digital presence, without having a physical one;
- (b) if so, the details thereof; and
- (c) If not, the measures proposed to be taken by the Government to deal with the multinationals which generate substantial revenues in India but do not share a proper share of taxes with the Government?

### Answered on 14<sup>th</sup> March 2022

- A.** (a), (b) & (c): Yes Sir. Finance Act, 2016 introduced an Equalisation Levy on specified services i.e. online advertisement provided by a non-resident not having physical presence in India. Finance Act, 2020 expanded the scope of Equalisation Levy to cover consideration received or receivable by an e-commerce operator from e-commerce supplies or services. Further, Section 9(1)(i) of the Income-tax Act, 1961 was amended vide Finance Act, 2018 and subsequently vide Finance Act, 2020 to provide for the concept of "Significant Economic Presence" ('SEP'), in addition to the existing concept of physical presence, for establishing a business connection in India of a non-resident.

The issue of taxation of income of multinational companies arising from digital presence has been considered by G20/Organisation for Economic Co-operation and Development (OECD) Inclusive Framework of which India is a member. A statement outlining the broad features of consensus based on a two-pillar solution was issued on 8th October, 2021 by the Inclusive Framework.

**The Minister of State in the Ministry of Finance  
(Sh. Pankaj Choudhary)**

---

## Pollution Control Scheme

---

### Lok Sabha Unstarred Question No: 1982

**Ms. Diya Kumari:**

**Q.** Will the Minister of **ENVIRONMENT, FOREST AND CLIMATE CHANGE** be pleased to state:

- (a) the details of the different Central and State Government agencies that are part of the Control of Pollution Scheme and their specific roles;
- (b) the details of funding along with their sources for Control of Pollution Scheme, including amount of funds allocated, amount utilised and areas of utilization;
- (c) whether there exists a central coordination mechanism to streamline the funding received from various sources and coordinate the functions of various Central and State Government agencies, if so, the details thereof; and
- (d) if not, the reasons therefor including any measure proposed to be taken in this regard?

### Answered on 14<sup>th</sup> March 2022

- A.** (a) and (b): Under the Central Sector Scheme (CSS) 'Control of Pollution, funds are released to different Central and State government agencies which inter alia include Central Pollution Control Board (CPCB), State Pollution Control Boards (SPCBs)/ Pollution Control Committees (PCCs) for various sub-components viz. Assistance for Abatement of Pollution in lieu of Water Cess funds subsumed with GST; National Clean Air Programme (NCAP);

Environmental Monitoring Programme; Assistance for Abatement of Pollution & Ongoing projects under the CETP and CT Scheme; Research Programmes and Outreach Activities.

The details of funding are at Annexure-I.

(c) and (d): Following Committees have been constituted under NCAP for Co-ordination at Central and State Level:

At the Central level : Apex Committee, Steering Committee, Monitoring Committee, and Implementation Committee;

At the State level : Steering Committees and Implementation Committees;

At the City level : Implementation Committees and Monitoring Committees.

There is a Project Appraisal Committee also for appraising individual project proposals of the centrally sponsored scheme 'Control of Pollution in the Ministry.



**Yearly funds status of Control of Pollution scheme**

(Amount in Crore Rs.)

Year	Funds allocated (BE)	Funds allocated (RE)	Funds released (Actual)
2019-20	460.96	445.00	408.86
2020-21	460.96	267.50	267.41
2021-22	470.00	390.10	251.98*

\*Funds released up to 28.02.2022

**Minister of State in the Ministry of Environment, Forest and Climate Change (Shri Ashwini Kumar Choubey)**

**Amendment to NDPS Act, 1985**

**Lok Sabha Unstarred Question No. 1862**

**Shri Pradyut Bordoloi:**

**Q.** Will the Minister of **FINANCE** be pleased to state:

- whether the Government proposes to amend the Narcotic Drugs and Psychotropic Substances (NDPS) Act to decriminalise usage of personal consumption of drugs, treating drug consumers as victims rather than culprits, as recommended by the Ministry of Social Justice and if so, the details thereof;
- whether the Government intends to amend the NDPS Act to distinguish between addicts, first-time users and recreational drug users and if so, the details thereof;
- the details of expenditures incurred on the National Fund for Control of Drugs Abuse between 2014 and 2021 year-wise;
- whether the National Fund for Control of Drugs Abuse is utilised for any de-addiction programs and if so, details thereof, and if not, reasons therefor; and
- whether the Government is undertaking any rehabilitation and harm-reduction measures for drug addicts in the North East region particularly and if so, the details thereof?

**Minister of State in the Ministry of Finance (Shri Pankaj Choudhary)**

- A.**
- No such proposal is pending currently.
  - Does not arise.
  - The details of expenditure incurred on the NFCDA between 2014 and 2021 year-wise are as under:

**Total amount released Financial Year-wise from 01.04.2014 to 31.03.2021 (in Rs.)**

2014-15	1,17,48,000/-
2015-16	43,86,950/-
2016-17	8,41,00,000/-
2017-18	58,74,628/-
2018-19	0/-
2019-20	0/-
2020-21	48,90,000/-
Total	11,09,99,578/-

(d) The details of NFCDA fund utilized for de-addiction programs so far are as under:

Organization	Amount Released
PGIMER, Chandigarh/for expansion of services of Drug De-addiction & Treatment Center at PGIMER, Chandigarh	2,22,00,000/-
India Red Cross Society, Kapurthala / for De- addiction Center (Action Plan of Kapurthala District)	18,01,375/-
PGIMER (Dr. Ram Manohar Lohia Hospital, New Delhi/for expansion of the de-addiction services)	36,20,000/-
Govt. of Arunachal Pradesh to set-up drug de- addiction Centres	50,00,000/-

(e) Ministry of Social Justice and Empowerment (MSJE), Government of India has been implementing the scheme of National Action Plan for Drug Demand Reduction (NAPDDR), under which financial assistance is provided to 'State Governments/ Union Territory (UT) Administrations and NGOs for running various projects concerning de-addiction programmes. A total of 98 such projects are being supported by Gol in the North Eastern states.

Furthermore, MSJE has also proposed to open 290 District De-Addiction Centre (DDAC) in various districts of the country, including various districts in the North- East Region.

MSJE has also launched Nasha Mukta Bharat Abhiyaan (NMBA) in 272 identified vulnerable districts. Among these, 46 districts have been identified as vulnerable in North-East Region under NMBA.

**Minister of State in the Ministry of Finance (Shri Pankaj Choudhary)**

## A licence to treat India's health sector



Gol's decision to stay on course with administering an examination - the National Exit Test (NExT) - for obtaining a licence to practise medicine is welcome. Tens of thousands go to Russia, China, Ukraine (90% of the 20,000-odd Indian students in this war-wracked country were studying medicine), Kyrgyzstan, the Philippines, etc, every year to pursue a degree in medicine. Within India, a sizeable number receive their medical education in private and public institutions. Ensuring that all medical graduates meet a minimum threshold of competence before being allowed to practise is essential to ensure a robust healthcare system.

The idea of a licence to practise for all medical graduates, irrespective of where they received their training, is a robust and fair way to ensure threshold quality.

Requiring even domestically trained medical students to take the exam creates a level playing field. The first examination will be held in 2023. The decision to have a trial run in 2022 makes eminent sense, as it will help iron out any hitches that could arise ahead of the rollout in 2023. The decision to have a trial run in 2022 makes eminent sense, as it will help iron out any hitches that could arise ahead of the rollout in 2023. This system will also help identify institutions that are below par and be an invaluable tool for the medical education commission to suggest measures and put out advisories for students. It could well spark a race to improve quality of education.

Healthcare, as the pandemic made doubly clear, has been a neglected sector. India had to mend and build its fragile system on the run. Personnel is the most critical part of this system. Ensuring this system is staffed with enough hands possessing at least a basic level of competence and training is the first step towards sprucing up India's health infrastructure. The licence system could ensure that in a fair, competent fashion.

Source: ET Bureau, 13.03.2022



## NOW AVAILABLE ! IDMA-APA GUIDELINES / TECHNICAL MONOGRAPHS

TECHNICAL MONOGRAPH NO. 1  
**STABILITY TESTING OF EXISTING DRUGS SUBSTANCES AND PRODUCTS**

TECHNICAL MONOGRAPH NO. 3  
**INVESTIGATION OF OUT OF SPECIFICATION (OOS) TEST RESULTS**

TECHNICAL MONOGRAPH NO. 5  
**ENVIRONMENTAL MONITORING IN CLEANROOMS**

TECHNICAL MONOGRAPH NO. 7  
**DATA INTEGRITY GOVERNANCE**

TECHNICAL MONOGRAPH NO. 2  
**PRIMARY & SECONDARY CHEMICAL REFERENCE SUBSTANCES**

TECHNICAL MONOGRAPH NO. 4  
**PHARMACEUTICAL PREFORMULATION ANALYTICAL STUDIES**

TECHNICAL MONOGRAPH NO. 6  
**CORRECTIVE/PREVENTIVE ACTIONS (CAPA) GUIDELINE**

TECHNICAL DOCUMENT NO. 8  
**QUALITY 4.0 DIGITAL TECHNOLOGY OF THE FUTURE**

Copies are available at IDMA Office, Mumbai. We do not mail any publications against VPP payment. All payments to be made in advance as Cheque/DD/RTGS/NEFT in favour of "INDIAN DRUG MANUFACTURERS' ASSOCIATION" at Mumbai.

For more details please contact: **PUBLICATIONS DEPARTMENT** Tel.: 022 - 2494 4624 / 2497 4308 Fax: 022 - 2495 0723  
E-mail: [publications@idmaindia.com](mailto:publications@idmaindia.com), Website: [www.idma-assn.org](http://www.idma-assn.org)/[www.indiandrugsonline.org](http://www.indiandrugsonline.org)

# INFINITE APPLICATIONS. **ONE IDENTITY.**

---

Dear Partner,

For over three decades, we have been dedicating ourselves to the pharmaceutical excipients industry in India. Three decades of relentless effort that has become our identity.

Today, that effort is evident in hundreds of applications across the arena of pharma, nutra and biopharma. And we are renewing our pledge to further enforce our efforts by focusing on one area - excipients. So we can continue to serve the industry and our partners even better, with greater efficiency and deeper integration.

Because while what we do leads to infinite ends, our identity remains uniquely unchanged - excipients.

Signet-ure

*Identity*

**Signet**

The Complete Excipients Company





## True experts love a challenge



### Aptar Pharma Taking on injectable complexities

Isn't our industry all about taking on challenges and pushing boundaries? Imagine just how dull life would be if we never tried to be better? Settling for the perceived standard is essentially settling for second best, and no-one can afford to do that.

Rest assured, taking on a complex injectable challenge doesn't have to be a risk. For over 50 years, our injectable specialists have led the way in developing innovative elastomer solutions. Their commitment to continuous improvement has resulted in elastomer formulations, which today feature best in class extractables and leachables profiles.

But we know that isn't enough. As the pharmaceutical industry continues to develop more sensitive and expensive drugs, we need to go further. That's why we have developed the Premium portfolio of injectable components.

To find out more about how we can help you address your next injectable challenge, call **Adam Shain**, Director, Global Business Development at Aptar Pharma or **+1 908-458-1782** or email **adam.shain@aptar.com**

Delivering solutions, shaping the future.

**Aptar**   
pharma